Frankfurt
09.01.26 | 08:05
3,240 Euro
+0,15 % +0,005
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Orexo AB: Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv | 158 | GlobeNewswire (Europe) | · An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closing... ► Artikel lesen | |
| 23.10.25 | Earnings Call zu Orexo AB: Aktie bricht nach Umsatzverfehlung im dritten Quartal 2025 ein | 2 | Investing.com Deutsch | ||
| OREXO Aktie jetzt für 0€ handeln | |||||
| 23.10.25 | Orexo Q3 2025 slides: Revenue miss overshadows AmorphOX pipeline progress | 1 | Investing.com | ||
| 23.10.25 | Orexo AB Q3 Loss Narrows | 1 | RTTNews | ||
| 23.10.25 | Orexo AB: Orexo Q3 2025 Interim Report | 127 | GlobeNewswire (Europe) | Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with... ► Artikel lesen | |
| 01.10.25 | Orexo AB: Orexo strengthens innovation and research with move to new premises | 108 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen | |
| 30.09.25 | Orexo US Awarded $8M in Funding by BARDA | 1 | Contract Pharma | ||
| 29.09.25 | Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership | 322 | GlobeNewswire (Europe) | Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical... ► Artikel lesen | |
| 05.09.25 | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 973 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
| 29.08.25 | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 386 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
| 16.07.25 | Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds | 1 | Investing.com | ||
| 16.07.25 | Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest | 1 | Investing.com Deutsch | ||
| 16.07.25 | Orexo AB: Orexo Q2 2025 Interim Report | 277 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
| 02.06.25 | Orexo to present clinical data for OX640 at the EAACI Congress | 313 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
| 06.05.25 | Orexo AB: Orexo Q1 2025 Interim Report | 298 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
| 10.04.25 | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 468 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
| 06.02.25 | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 252 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,650 | -0,27 % | CBD-Markt auf Wachstumskurs: Neural Therapeutics und Hanf.com positionieren sich strategisch | ||
| ABBVIE | 189,20 | -1,66 % | Börsenfrühstück: Defense, AbbVie, Micron & Exxon | Marktbeicht für den 08.01.2026: Die internationalen Aktienmärkte zeigen sich nach dem starken Jahresstart uneinheitlich. In den USA schloss der S&P 500 am Mittwoch leicht im Minus, während der Nasdaq... ► Artikel lesen | |
| TILRAY BRANDS | 7,881 | +0,29 % | Börsenfrühstück: Glencore & Rio Tinto, GM und Tilray | Marktbericht für den 09. Januar 2026: Die internationalen Märkte zeigen sich zum Wochenausklang abwartend. Investoren halten sich vor den anstehenden US-Arbeitsmarktdaten zurück, die maßgeblich für... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 47,970 | -0,03 % | Scotiabank raises Bristol-Myers Squibb stock price target to $60 on growth | ||
| TEVA | 27,500 | -1,43 % | Teva Pharmaceutical Industries Ltd: Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference | TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th... ► Artikel lesen | |
| BAUSCH HEALTH | 6,500 | -2,72 % | Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference | ||
| BIONANO GENOMICS | 1,580 | 0,00 % | Bionano Genomics: Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. "Over the last year, we have taken... ► Artikel lesen | |
| OPKO HEALTH | 1,183 | +1,01 % | OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth | ||
| JAGUAR HEALTH | 1,050 | -2,78 % | Jaguar Health, Inc.: Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication | Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated... ► Artikel lesen | |
| KEENOVA THERAPEUTICS | - | - | Mallinckrodt Reports Third Quarter 2025 Financial Results | Delivers Third Quarter Net Sales of $753.1 Million, Driven by Acthar® Gel (repository corticotropin injection) Growth and the Inclusion of Two Months of Endo Product... ► Artikel lesen | |
| AVALO THERAPEUTICS | 14,880 | +1,22 % | Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa | WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1ß-based treatments for immune-mediated... ► Artikel lesen | |
| BAYER | 38,880 | -1,66 % | Bayer-Aktie steigt: Kursziel bei 41 Euro | Die Bayer-Aktie startet mit einem Kursplus von 2,45 Prozent ins neue Börsenjahr und bestätigt damit den Aufwärtstrend aus 2025. Starke Gewinnprognosen und ein klarer technischer Aufwärtstrend treiben... ► Artikel lesen | |
| NOVO NORDISK | 50,60 | +2,47 % | Novo Nordisk Aktie: Zündet jetzt die Kursrally?! Sind 70 oder 80 Euro möglich? | © Foto: Bild von Willfried Wende auf PixabayDas Jahr 2025 war für Novo Nordisk ein echter Dämpfer. Die Aktie verlor heftig und rutschte von ihrem Allzeithoch deutlich in niedrigere Gefilde.Doch zum... ► Artikel lesen | |
| MERCK KGAA | 128,30 | +0,47 % | Zukunft der Krebstherapie: Warum diese NASDAQ-Aktie jetzt im Januar eine außergewöhnliche Einstiegschance bietet | ||
| AQUESTIVE THERAPEUTICS | 3,935 | -36,84 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update | Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency's review of Anaphylm... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.